Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Some things don't change...
This stock hasn't moved or made big changes in the last 3 years.
All talk no results.
Hemorrhaging money.
You have 2 shady characters reuniting after running a Telecom company to the ground (Trujillo and Waggoner)
Why waste your $ here?
This last SMM PR blast looks familiar...
www.stockmarketmediagroup.com/nuvilex-inc-moves-closer-to-head-to-head-with-eli-Eli Lilly in Phase III Clinical Trials
Written by ? Stock Market Media Group Staff — July 25, 2013
Nuvilex, Inc. (OTCQB: NVLX) is currently preparing the way to challenge Eli Lilly’s (NYSE: LLY) blockbuster cancer drug, Gemzar, and doing so with the knowledge that in two independent mid-phase clinical trials, the company’s treatment involving its proprietary living cell encapsulation technology has outperformed the pharmaceutical giant. Nuvilex has produced better results when compared to historical data for Gemzar, and now the company is ready to use real time, head to head data to prove its treatment is superior to Eli Lilly’s.
NEW YORK, NY--(Marketwired - January 24, 2017) - Ten years ago the National Cancer Institute (NCI) recognized the rise in pancreatic cancer deaths and called for the development of better treatments. The NCI encouraged developers to design more clinical trials that don't use the chemotherapy drug gemcitabine as part of their treatment. PharmaCyte Biotech (OTCQB: PMCB) is on the doorstep of doing just that -- developing a treatment that doesn't use gemcitabine, and instead the company has designed a clinical trial that will actually go head to head with gemcitabine.
Stock dilution. It's what this company lives and breathes on. Its been ovrr 2 years and slowly draining this stock. Move on. There are a lot better stocks out there.
I feel bad for everyone still in this stock. No matter if you've been in it for 2 years, a year or a month there's no difference. You're in the red. They keep touting by getting patents but who wants a patent on a device that's technology has been around since the 90s and nothing has come out of it? No big buy out or big clinical trials. People are expected to believe this is just a lost gem that's no one has given a chance to shine. Very sad and very unfortunate. The only people who have made real money off this stock were early pre February 2013 buyers and the board who paid themselves handsomely.
Wow I can buy shares cheaper in 2016 than in 2014. That's 2 years of development. Sounds like this stock was blowing hot air or should I say, pumping?
No way! "Enter Warren Buffet quote here" Great buying period! This whole years been a great buying period
It's been upcoming for a year and a half now.
This thing still hasn't gotten it's tires out of the mud. Money will run out before they even start trials
Premium sale if you're PMCB. I remember people saying buying PMCB at .30 was a steal, then .25 then .20 .15 .10 .08 .07?
At 2 cents
Might as well keep your money in PMCB. It's probably too late for most to sell without a major loss.
Another puff piece using clinical trials that have been confirmed by the SEC and PMCB to have no scientific value.
Clinical trials take a few months? Really? Yet getting Austrianovas facility approved for trials is taking....almost a year?
Is PMCB even screening patients for their trials right now? The FDA and SEC want large trials in order for the data to be considered significant.
A few months? A few years....
Efficacy? Prove it. Because the phase 1 and 2 trials from back and the day have been stated to have little to no scientific value according the PMCB and the SEC. Both have agreed to this.
They only steamed up because they touted Marijuana articles when pot stocks were jumping. They were featured in penny pot stock articles. They tried to say they could have a deal with the NFL in the future lol. That was January 2014 yes KW was CEO.
Look at CBIS, MJNA, TRTC, etc all spiked at the same time as NVLX(PMCB) and dropped just as fast. KW changed the ticker/created a fake merger to PMCB in a blink of an eye so it's chart doesn't go back as far.
Same thing happened with Chinatel to VelaTel. Coincidence Carlos Trujillo, Tim Matula and Kenneth Waggoner were all part of ChinaTel/VelaTel?
But you have to admit that PMCB doesn't own the facility. At the most it would generate 14.5% of what Austrianova is making off of it.
And don't expect the facility to be approved for another 6 months at least.
Not being crucial at all even PMCB stated that Aus is in the beginning phase of it being overlooked.
What facilities? Oh you mean the office space they rent out which they claim they hardly are ever at? Or AUSTRIANOVAS facility? Because I do not see a building under their long term assets.
Of course there is support here if you look at the 10k of 2014 and 13 they were pretty much giving away shares at .03 - 08 to insiders.
Forcing yourself to keeping buying so you stay above water isn't the best advice I would give someone. Good luck!
PMCB needs to start European trials by July 2016 in order to keep their license via most recent 10k.
That EMA withdrawal looks pretty bad at this point.
Because all the insiders are at .05 - .08
Carlos Trujillo is getting the same amount of compensation as Crabtree is for his "services" really?
CJ was at ChinaTel with Tim Matula and Kenneth Waggoner before it went under and now he suddenly appears here?
PMCB also needs to start European trials before the end of the first half of 2016 or their license goes away :( them withdrawing their fast track application with the EMA doesn't look too good now.
KW used to be a "advisor" and was on the board at LIVE. Who has a Shelf Agreement with Chardan.
LIVE where Tim Matula is currently at. Who used to work at NVLX before KW was brought in as CEO. Tim left NVLX last September with 10 million shares if I remember correctly.
Both KW and Tim Matula used to work at ChinaTel and VelaTel together before their ship sank.
Weird thing I found out reading this most recent 10k is that Carlos Trujillo has now some stake in PMCB. Carlos used to be part of ChinaTel as well. Chinatel has a crazy story in itself.
Last thing also, LIVE's CEO is Jon Isaac, Isaac holding was named as the potential buyout of Chinatel before everything caved in and everyone ran with inflated shares prices due to rumor of a buyout that was never going to happen.
I wish I could post more than once a day on this board but I'm writing up a nice piece just looking for a little more :)
CARLOS TRUJILLO HAS HIS HAND IN PMCB TOO
Connection? He used to work with Kenneth Waggoner at Chinatel and VelaTel named in insider trading along with KW. Look it up. WOW.
Check the most recent 10k
Also PMCB needs to do European trials in order to keep cell in a box license via 10k uh oh didn't they withdraw from EMA? Need to start in less than a year
August 1st 2014 marked the beginning of the first preclinical trial.
.28 after a big drop from the mid 30s when they released old dog trials.
it hasn't recovered since.
Reverse Split by the beginning of next year.
Money in PMCB is dead money at this point. So many other biotechs with bigger gains but I guess if you like penny stocks sure a couple 10% jumps followed by 10% drops the next day might be fun?
First rat trials (This decade) started August 1st 2014 PPS was @ .28 after a large drop from the .40s after they released old dog trials.
Only way this is getting to a dollar is a Reverse split. It's going to happen sooner than later.
Buyout for .20 a share is the most PMCB will get.
Watch it go down 10% today, I'll say at least 5
People have been saying that since last year this time when it was in the 40s 30s 20s still not low enough? Must not be worth much if .05 is where it has to be in order to make money. If this stock was with 4 or 5 dollars why would a few cents matter?
You know what I would, but I don't think I have enough experience in moving from penny stock to penny stock to be qualified for the job.
Sounds like they're hiding something not trying to release the trials individually. Back to .08 soon.
Wonder how much they paid for that little piece. Let's see how today turns out
Too bad the SEC did it to the only leg PMCB was standing on. I predicted .10 but not THIS fast. I was expecting a jump before that.
It's fine longs will ride this like the captain of the Titanic.
Too bad I believe the captain of PMCB will leave this coming November...
Read my previous post. The SEC made them state that those trials were so small that it's possible it was due to chance alone.
PMCB even stated that those trials weren't done to determine effective or to even go to the market.
there's no real proof that Ciab with ifosfamide beat the gold standard the SEC even said so!!
In other news NVIV is doing amazing.
PMCB? When the SEC forces you to say your one and only clinical trials results, (where the "well its been proven to beat the gold standard" comes from) could be merely because of chance? Ouch.
I see another rally for PMCB coming, but they just keep getting smaller and smaller.
Waggoner having to answer the SEC's questions twice should tell you something
2nd round of questions
In our prior comment 3, concerning the small number of patients treated in the Phase 1/2 trial, we referred to response #7 from your August 15, 2014 letter. In that response, you included proposed disclosure which began:
In the Phase1/2 trial only a small number of patients were evaluable. As a result, statistical parameters were not used in the published reports of the Phase 1/2 trial to validate the anticancer efficacy of the Cell-in-a-Box/low-dose ifosfamide combination in patients with advanced, inoperable pancreatic cancer…
Please delete the sentence from your proposed disclosure that states “It is unlikely, even with the small number of patients…that the increases in median survival time and percentage of one-year survivors …were due to chance alone….” This is a statement of opinion that purports to be factual in nature and is, therefore, inappropriate. Since statistical significance could not be measured in this trial, you cannot exclude the possibility that the results were due to chance. Therefore, please replace the sentence quoted above with a statement explaining that because the results were not statistically significant, any observations of efficacy must be weighed against the possibility that the results were due to chance alone.
Mr. Jeffrey P. Riedler
Assistant Director
Securities and Exchange Commission
Page 3
RESPONSE: As requested, the proposed disclosure will be revised to state as follows (marking reflects changes to the version proposed in our letter of August 15):
“In the Phase1/2 trial only a small number of patients were evaluable. As a result, statistical parameters were not used in the published reports of the Phase 1/2 trial to validate the anticancer efficacy of the Cell-in-a-Box/low-dose ifosfamide combination in patients with advanced, inoperable pancreatic cancer. In the opinion of the investigators, the results indicate a trend towards efficacy, so the results should not be viewed as absolute numbers. It is unlikely, even with the small number of patients used, that the increases in median survival time and percentage of one-year survivors that were seen in the trial were due to chance alone given the advanced nature of the patient’s cancers and the knowledge that, without treatment, those numbers would not have occurred. It should be noted, however, that because the results were not statistically significant, any observations of efficacy must be weighed against the possibility that the results were due to chance alone. The purpose of the trials was not to obtain data so that we could seek marketing approval from regulatory authorities, but rather the trials allowed us to determine whether the Cell-in-a-Box/low-dose ifosfamide combination holds promise as a treatment for pancreatic cancer. In the cancer arena, Phase 1/2 trials are used to first establish the safety of drug or treatment being investigated and second to determine if a trend towards efficacy exists. In accordance with FDA guidance, as well as similar guidance from other regulatory authorities in countries other than the United States, we fully realize that a large, multicenter, randomized, comparative study with statistically powerful findings would need to be conducted and the results from such a trial would have to confirm those from the previous Phase 1/2 trial before an application for marketing approval would be made for the Cell-in-a-Box/low-dose ifosfamide combination as a treatment for advanced, inoperable pancreatic cancer.”
http://www.sec.gov/Archives/edgar/data/1157075/000101968714003803/filename1.htm
http://www.sec.gov/Archives/edgar/data/1157075/000101968714003235/filename1.htm
.12 coming... .10 is not too far away. Get ready for a penny stock promoter to cook up a nice "review". Until then it's blame shorts and MMs.
Remission for only days 2 through 6? What about the rest of the days? Did it stop working? The cancer seems to have come back day 7 and never went back to complete remission for the rest of the trial.
Also like other drug delivery systems would Ciab have to go through trials for every drug it would be combined with?